Professor Michael O'Dwyer
Prof. Michael O’Dwyer is a Clinician Scientist with expertise in translational research in haematologic oncology. He established a translational research programme in Multiple Myeloma at NUI Galway and established Blood Cancer Network, Ireland (BCNI), focusing on delivery of early phase clinical trials along with establishment of a biobank and registry for blood cancers.
Prof. O’Dwyer leads a research group with a focus on gaining new biologic insights and developing new therapeutic strategies in Multiple Myeloma and other cancers. The three major areas of focus are: (1) translational glycobiology in cancer (3) reversing immune tolerance/suppression in the tumour microenvironment (3) use and modification of natural killer (NK) cells as cell therapy for cancer.
His clinical research focus is on translating these research findings into innovative phase I and II studies through Blood Cancer Network Ireland thereby giving Irish patients access to novel therapies that would not otherwise be possible. The focus is on understanding and developing novel new immune therapies for cancer, especially Multiple Myeloma and AML.
Prof. O’Dwyer contributed to the early clinical development of Imatinib (Gleevec) with Brian Druker which was the first effective molecular targeted therapy. He established a translational program of research in multiple myeloma at NUI Galway where his work on glycosylation has provided new insights into the biology of multiple myeloma.
He established and is director of BCNI and leads the development of phase I trial capability in Ireland in blood cancers.
Prof. O’Dwyer has published more than 70 papers in peer-reviewed journals, filed > 6 patent applications and is the Founder of Onkimmune, a start-up company focusing on NK cells as anti-cancer therapy.
Prof. O’Dwyer is the director of Blood Cancer Network Ireland, and Chair Haematology and Lymphoma DSSG at Cancer Trials Ireland. He acts as a reviewer for journals including Blood, Cancer, Leukemia, Haematologica, Biology of Bone Marrow Transplantation and as a Grant Reviewer for Cancer Research UK, and MMRF. He is a member of the American Society of Hematology (ASH), European Society of Hematology (EHA), International Myeloma Working Group (IMWG), serves on the Scientific Advisory Board of Carrick Therapeutics and is Chief Scientific Officer of OnkImmune.
+353 (0) 91 495833